UK markets closed

Centessa Pharmaceuticals plc (CNTA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.7000-0.1900 (-3.89%)
As of 01:54PM EDT. Market open.

Centessa Pharmaceuticals plc

1 Ashley Road
3rd Floor
Altrincham WA14 2DT
United Kingdom
44 203 9206789
https://www.centessa.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees90

Key executives

NameTitlePayExercisedYear born
Prof. James Huntington Ph.D.Co-Founder and Chief Scientific Advisor of ApcinteX & Z Factor204.85kN/AN/A
Dr. James Edward Coleman Ph.D.Co-Founder & COO of LockBody Therapeutics163.88kN/AN/A
Dr. Trevor Baglin Ph.D.Co-Founder, Chief Medical Officer - ApcinteX & Chief Medical Officer - Z Factor65.55kN/AN/A
Dr. Nicholas Morrell M.D., MBBSCo-Founder & CEO of Morphogen-IX320.94kN/AN/A
Dr. William James Jonathan Finlay B.Sc., Ph.D.Co-Founder & CEO of LockBody Therapeutics163.88kN/AN/A
Dr. Saurabh Saha M.D., Ph.D.CEO & DirectorN/AN/A1977
Dr. Gregory M. Weinhoff M.B.A., M.D., MBAChief Financial OfficerN/AN/A1971
Ms. Marella ThorellChief Accounting OfficerN/AN/A1967
Dr. Thomas S. Templeman Ph.D.Chief Technology OfficerN/AN/A1960
Dr. David M. Chao Ph.D.Chief Admin. OfficerN/AN/A1968
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.

Corporate governance

Centessa Pharmaceuticals plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.